Amycretin research peptide
CAS 3005889-81-3 · ≈ 7846.58 g/mol
GLP-1 / amylin receptor co-agonist. Investigational; in clinical development and not yet approved by the US FDA, EMA or other major regulators for any indication.
Winhycare Pharma · Research use only
GLP-1, GIP and glucagon receptor agonists studied in metabolic research. Winhycare Pharma supplies each of these peptides as research-grade material at >99% purity with QC documentation, for laboratory research use only.
CAS 3005889-81-3 · ≈ 7846.58 g/mol
GLP-1 / amylin receptor co-agonist. Investigational; in clinical development and not yet approved by the US FDA, EMA or other major regulators for any indication.
CAS 2259884-03-0 · 4563.14 g/mol
GLP-1 / glucagon dual receptor agonist. Approved as an active ingredient by China's NMPA (chronic weight management, 2025; glycaemic control in type 2 diabetes, 2025). Outside China it remains investigational and in late-stage clinical development, not yet approved by the US FDA or EMA.
CAS 2381089-83-2 · 4731.33 g/mol · also supplied as API
GLP-1 / GIP / glucagon triple receptor agonist. Investigational; in clinical development (Phase 3) and not yet approved by the FDA, EMA or any regulator for any indication.
CAS 910463-68-2 · 4113.58 g/mol · also supplied as API
GLP-1 receptor agonist (acylated 31-amino-acid peptide). Approved as an active ingredient by major regulators including the US FDA and EMA for type 2 diabetes and chronic weight management.
CAS 2805997-46-8 · 4231.69 g/mol
GLP-1 / glucagon dual receptor agonist. Investigational; in clinical development (Phase 3) and not yet approved by the FDA, EMA or other major regulators. It has received US FDA Breakthrough Therapy designation and EMA PRIME access in MASH, but its efficacy and safety have not been established for therapeutic use.
CAS 2023788-19-2 · 4813.53 g/mol · also supplied as API
GIP / GLP-1 dual receptor agonist. Approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes).
| Peptide | CAS | Molecular weight | Sequence | Purity |
|---|---|---|---|---|
| Amycretin | 3005889-81-3 | ≈ 7846.58 g/mol | 68 amino acids (unimolecular GLP-1 and amylin receptor agonist moieties joined by a short Gly/Glu linker) | >99% |
| Mazdutide | 2259884-03-0 | 4563.14 g/mol | 39 amino acids (oxyntomodulin analogue; Aib at position 2, acylated with a C20 di-acid side chain via AEEA-γGlu linker) | >99% |
| Retatrutide | 2381089-83-2 | 4731.33 g/mol | 39 amino acids (acylated with a C20 fatty di-acid side chain at Lys17) | >99% |
| Semaglutide | 910463-68-2 | 4113.58 g/mol | 31 amino acids (acylated with a C18 fatty di-acid side chain) | >99% |
| Survodutide | 2805997-46-8 | 4231.69 g/mol | 29 amino acids (acylated with a C18 fatty di-acid side chain) | >99% |
| Tirzepatide | 2023788-19-2 | 4813.53 g/mol | 39 amino acids (acylated with a C20 fatty di-acid side chain; C-terminal amide) | >99% |
Research use only. Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics. Buyers are responsible for complying with the import and use regulations of their country.
Amycretin, Mazdutide, Retatrutide, Semaglutide, Survodutide, Tirzepatide, each at >99% purity for research use only.
No. They are supplied for laboratory research use only and are not for human or veterinary use. We do not provide dosing or usage advice.
Material is supplied with QC documentation. Tell us in your enquiry what your lab or quality team needs.
Yes. Include the quantity in your enquiry; bulk and distributor quantities are quoted on request.
Products & services
Guides










